52 related articles for article (PubMed ID: 27387538)
1. Effect of tubeimoside I on the activity of cytochrome P450 enzymes in human liver microsomes.
Wang R; Zheng K; Liu Y; Ji S; Tang Y; Wang J; Jiang R
Xenobiotica; 2024 Feb; 54(2):57-63. PubMed ID: 38166553
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of the main metabolites of Apatinib on CYP450 isozymes in human and rat liver microsomes.
Pang NH; Xu RA; Chen LG; Chen Z; Hu GX; Zhang BW
Toxicol In Vitro; 2024 Mar; 95():105739. PubMed ID: 38042355
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
4. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19.
Hou L; Zhao Y; Zhao S; Zhang X; Yao X; Yang J; Wang Z; Chan ECY; Liu S
Chem Biol Interact; 2024 Jan; 387():110811. PubMed ID: 37993078
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).
Nasrin S; Coates S; Bardhi K; Watson C; Muscat JE; Lazarus P
Chem Res Toxicol; 2023 Feb; 36(2):177-187. PubMed ID: 36626330
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel.
Kapungu NN; Li X; Nhachi C; Masimirembwa C; Thelingwani RS
Pharmacol Res Perspect; 2020 Aug; 8(4):e00618. PubMed ID: 32700798
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of human cytochrome P450 enzymes by licoisoflavone B from Glycyrrhiza uralensis Fisch. ex DC.
Chen L; Nikolic D; Li G; Liu J; van Breemen RB
Toxicol Sci; 2023 Oct; 196(1):16-24. PubMed ID: 37535691
[TBL] [Abstract][Full Text] [Related]
8. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors.
Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT
Eur J Pharm Sci; 2024 Feb; 198():106735. PubMed ID: 38423227
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of mono Cytochrome P450 in a modified CHO-CPR cell-free protein production platform.
Knauer JF; Schulz C; Zemella A; Wüstenhagen DA; Walter RM; Küpper JH; Kubick S
Sci Rep; 2024 Jan; 14(1):1271. PubMed ID: 38218994
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Nitration Contributes to Nitric Oxide-Stimulated Degradation of CYP2B6.
Lee CM; Wilderman PR; Park JW; Murphy TJ; Morgan ET
Mol Pharmacol; 2020 Sep; 98(3):267-279. PubMed ID: 32817462
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.
Havrylyuk D; Heidary DK; Glazer EC
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672458
[TBL] [Abstract][Full Text] [Related]
12. Enantioselective intramolecular C-H amination catalyzed by engineered cytochrome P450 enzymes in vitro and in vivo.
McIntosh JA; Coelho PS; Farwell CC; Wang ZJ; Lewis JC; Brown TR; Arnold FH
Angew Chem Int Ed Engl; 2013 Aug; 52(35):9309-12. PubMed ID: 23893546
[No Abstract] [Full Text] [Related]
13. In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies.
Saxena A; Jain GK; Siddiqui HH; Bhunia SS; Saxena AK; Gayen JR
Xenobiotica; 2014 Apr; 44(4):295-308. PubMed ID: 23992115
[TBL] [Abstract][Full Text] [Related]
14. Insight into stereoselective disposition of enantiomers of a potent antithrombotic agent, S002-333 following administration of the racemic compound to mice.
Bhateria M; Rachumallu R; Yerrabelli S; Saxena AK; Bhatta RS
Eur J Pharm Sci; 2017 Apr; 101():107-114. PubMed ID: 28189817
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profiling of a novel antithrombotic compound, S002-333 and enantiomers: metabolic stability, species comparison and in vitro-in vivo extrapolation.
Saxena A; Valicherla GR; Jain GK; Bhatta RS; Saxena AK; Gayen JR
Biopharm Drug Dispos; 2016 May; 37(4):185-99. PubMed ID: 26477787
[TBL] [Abstract][Full Text] [Related]
16. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jul; 12(6):549-69. PubMed ID: 21476971
[TBL] [Abstract][Full Text] [Related]
17. Inhibition and induction of cytochrome P450 and the clinical implications.
Lin JH; Lu AY
Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6.
Bhateria M; Ramakrishna R; Puttrevu SK; Saxena AK; Bhatta RS
Chem Biol Interact; 2016 Aug; 256():257-65. PubMed ID: 27387538
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
